Literature DB >> 26526586

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.

Laura K McMullan1, Mike Flint1, Julie Dyall2, César Albariño1, Gene G Olinger2, Scott Foster3, Phiroze Sethna3, Lisa E Hensley2, Stuart T Nichol1, E Randall Lanier3, Christina F Spiropoulou4.   

Abstract

Brincidofovir (BCV) is the 3-hexadecyloxy-1-propanol (HDP) lipid conjugate of the acyclic nucleoside phosphonate cidofovir (CDV). BCV has established broad-spectrum activity against double-stranded DNA (dsDNA) viruses; however, its activity against RNA viruses has been less thoroughly evaluated. Here, we report that BCV inhibited infection of Ebola virus in multiple human cell lines. Unlike the mechanism of action for BCV against cytomegalovirus and other dsDNA viruses, phosphorylation of CDV to the diphosphate form appeared unnecessary. Instead, antiviral activity required the lipid moiety and in vitro activity against EBOV was observed for several HDP-nucleotide conjugates.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Antiviral therapy; Brincidofovir; Ebola; In vitro screen

Mesh：

Substances：

Year:  2015        PMID： 26526586     DOI： 10.1016/j.antiviral.2015.10.010

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  16 in total

1.  Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.

Authors:  Stephen J Capuzzi; Wei Sun; Eugene N Muratov; Carles Martínez-Romero; Shihua He; Wenjun Zhu; Hao Li; Gregory Tawa; Ethan G Fisher; Miao Xu; Paul Shinn; Xiangguo Qiu; Adolfo García-Sastre; Wei Zheng; Alexander Tropsha
Journal:  J Med Chem       Date:  2018-04-17       Impact factor: 7.446

Review 2.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

3.  Experimental Therapies for Ebola Virus Disease: What Have We Learned?

Authors:  Frederick G Hayden; Martin Friede; Daniel G Bausch
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

4.  Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Authors:  Yu Cong; Julie Dyall; Brit J Hart; Lisa Evans DeWald; Joshua C Johnson; Elena Postnikova; Huanying Zhou; Robin Gross; Oscar Rojas; Isis Alexander; Nicole Josleyn; Tengfei Zhang; Julia Michelotti; Krisztina Janosko; Pamela J Glass; Mike Flint; Laura K McMullan; Christina F Spiropoulou; Tim Mierzwa; Rajarshi Guha; Paul Shinn; Sam Michael; Carleen Klumpp-Thomas; Crystal McKnight; Craig Thomas; Ann E Eakin; Kathleen G O'Loughlin; Carol E Green; Paul Catz; Jon C Mirsalis; Anna N Honko; Gene G Olinger; Richard S Bennett; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

5.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Authors:  Michael K Lo; Robert Jordan; Aaron Arvey; Jawahar Sudhamsu; Punya Shrivastava-Ranjan; Anne L Hotard; Mike Flint; Laura K McMullan; Dustin Siegel; Michael O Clarke; Richard L Mackman; Hon C Hui; Michel Perron; Adrian S Ray; Tomas Cihlar; Stuart T Nichol; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

6.  Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.

Authors:  Elena Postnikova; Yu Cong; Lisa Evans DeWald; Julie Dyall; Shuiqing Yu; Brit J Hart; Huanying Zhou; Robin Gross; James Logue; Yingyun Cai; Nicole Deiuliis; Julia Michelotti; Anna N Honko; Richard S Bennett; Michael R Holbrook; Gene G Olinger; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

7.  A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus.

Authors:  Mike Flint; Payel Chatterjee; David L Lin; Laura K McMullan; Punya Shrivastava-Ranjan; Éric Bergeron; Michael K Lo; Stephen R Welch; Stuart T Nichol; Andrew W Tai; Christina F Spiropoulou
Journal:  Nat Commun       Date:  2019-01-17       Impact factor: 14.919

8.  Novel amodiaquine derivatives potently inhibit Ebola virus infection.

Authors:  Yasuteru Sakurai; Norikazu Sakakibara; Masaaki Toyama; Masanori Baba; Robert A Davey
Journal:  Antiviral Res       Date:  2018-11-03       Impact factor: 5.970

9.  Experimental Treatment of Ebola Virus Disease with Brincidofovir.

Authors:  Jake Dunning; Stephen B Kennedy; Annick Antierens; John Whitehead; Iza Ciglenecki; Gail Carson; Rupa Kanapathipillai; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Jennifer Grove; Janet Scott; Trudie Lang; Piero Olliaro; Peter W Horby
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

10.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Authors:  Travis K Warren; Robert Jordan; Michael K Lo; Adrian S Ray; Richard L Mackman; Veronica Soloveva; Dustin Siegel; Michel Perron; Roy Bannister; Hon C Hui; Nate Larson; Robert Strickley; Jay Wells; Kelly S Stuthman; Sean A Van Tongeren; Nicole L Garza; Ginger Donnelly; Amy C Shurtleff; Cary J Retterer; Dima Gharaibeh; Rouzbeh Zamani; Tara Kenny; Brett P Eaton; Elizabeth Grimes; Lisa S Welch; Laura Gomba; Catherine L Wilhelmsen; Donald K Nichols; Jonathan E Nuss; Elyse R Nagle; Jeffrey R Kugelman; Gustavo Palacios; Edward Doerffler; Sean Neville; Ernest Carra; Michael O Clarke; Lijun Zhang; Willard Lew; Bruce Ross; Queenie Wang; Kwon Chun; Lydia Wolfe; Darius Babusis; Yeojin Park; Kirsten M Stray; Iva Trancheva; Joy Y Feng; Ona Barauskas; Yili Xu; Pamela Wong; Molly R Braun; Mike Flint; Laura K McMullan; Shan-Shan Chen; Rachel Fearns; Swami Swaminathan; Douglas L Mayers; Christina F Spiropoulou; William A Lee; Stuart T Nichol; Tomas Cihlar; Sina Bavari
Journal:  Nature       Date:  2016-03-02       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.